Comprehensive supportive care requires oncology nurses and advanced practice providers (APPs) to look beyond the physical manifestations of disease and address the broader needs of patients, explained ...

C, OCN, discusses planning beyond first-line CDK4/6 inhibitors and supportive care strategies for patients with HR+/HER2– ...

Subcutaneous daratumumab is well tolerated, but ongoing immune monitoring is key to managing infection risk in patients with ...

An LED-based intraoral device for photobiomodulation therapy was safe and reduced severe oral mucositis in patients with head ...

The FDA has approved imlunestrant for the treatment of patients with ESR1-mutated ER+, HER2- metastatic breast cancer.

Leaders in oncology nursing and advanced practice spotlight the essential role of advanced practice providers in oncology.

Subcutaneous pembrolizumab has been approved across all indications, cutting chair and administration times with a median ...

Caleb Raine, PA-C explains what BCMA is and why it is a common bispecific antibody target in multiple myeloma.

In an interview with Oncology Nursing News, Kirschner, who serves as the director of program development at the Cancer ...

BC, AOCNP, explains how ctDNA can inform prognosis, monitor disease progression, and guide treatment decisions in oncology.

C, OCN, discusses how patient comorbidities and adverse effect profiles guide CDK4/6 inhibitor choice in the first-line setting.